Piramal Pharma Limited has successfully acquired an additional 40.67% stake in Yapan Bio Private Limited, an associate company. This acquisition, for a cash consideration of approximately ₹76 crores, increases Piramal Pharma’s shareholding to 74.00%, thereby making Yapan Bio a subsidiary. The move aims to integrate Yapan Bio’s advanced large molecule capabilities into Piramal Pharma’s service offering, enhancing its capacity for complex biologic therapies.
Piramal Pharma Expands Biologics Capabilities with Yapan Bio Acquisition
Piramal Pharma Limited has announced the completion of its acquisition of an additional 40.67% equity stake in Yapan Bio Private Limited. This strategic move, communicated on 18th August 2026, significantly strengthens Piramal Pharma’s position in the biopharmaceutical sector.
Key Transaction Details
The acquisition involved the purchase of 1,46,400 equity shares of ₹10 each from existing shareholders for an aggregate cash consideration of approximately ₹76 crores. Following this transaction, Piramal Pharma’s shareholding in Yapan Bio has risen from 33.33% to 74.00% of its equity share capital. Consequently, Yapan Bio has transitioned from an associate company to a subsidiary of Piramal Pharma Limited.
Yapan Bio: A Strategic Asset
Yapan Bio Private Limited, incorporated on 11th October 2019, operates as a Contract Development and Manufacturing Organization. It specializes in process development, characterization, and Phase I/II GMP manufacturing services for vaccines and biologics. The company reported revenues of ₹26.91 crores in FY2024, ₹54.40 crores in FY2025, and ₹26.34 crores in FY2026.
Strategic Rationale and Future Impact
This acquisition is set to fully embed Yapan Bio’s advanced large molecule capabilities into Piramal Pharma’s integrated service offering. This integration is expected to enable Piramal Pharma to develop and scale complex biologic therapies with enhanced efficiency, further solidifying its competitive edge in the biologics market.
Source: BSE
